UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 421, 2011

GLOBAL PHARM HOLDINGS GROUP, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	333-152286	20-8767223
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

25/F New World Center, No. 6009 Yitian Road, Futian District, Shenzhen,

People’s Republic of China

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: 86-755-83230226

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 82.~~01 Other~~02 Results ~~Events~~of Operations and Financial Condition.

~~The~~On ~~Company,~~November a China-based leading vertically integrated pharmaceutical company engaged in pharmaceutical-related products distribution and Traditional Chinese Medicine herbs cultivation through its subsidiaries in Anhui21, ~~Jilin and Shandong provinces~~2011, ~~today~~Global ~~announced~~Pharm ~~that,~~Holdings ~~on October 31~~Group, ~~2011, it completed the acquisition of the 100% equity interest of Qingdao Likang Pharmaceutical Co~~Inc., ~~Ltd~~issued ~~(“Qingdao Likang”),~~ a ~~city-level~~press ~~pharmaceutical~~release ~~distributor~~to ~~located~~report inits ~~Qingdao,~~2011 ~~Shandong~~third ~~Province.~~quarter ~~With~~financial ~~the completion of this acquisition, Qingdao Likang becomes an indirect wholly owned subsidiary of the Company~~results.

Attached hereto as Exhibit 99.1 is the Press Release announcing the ~~acquisition~~2011 ofthird ~~Qingdao~~quarter ~~Likang~~financial ~~by the Company~~results.

~~Item~~ITEM 9.01 ~~Financial~~ FINANCIAL ~~Statements~~STATEMENTS ~~and~~AND ~~Exhibits~~EXHIBITS.

Exhibit 99.1 — Press Release dated November 421, 2011 announcing the ~~acquisition~~2011 ofthird ~~Qingdao~~quarter ~~Likang~~financial ~~by the Company.~~results

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 4, 2011	Global Pharm Holdings Group, Inc.
Date: November 21, 2011	Global Pharm Holdings Group, Inc.
By:	/s/ An Fu
	An Fu
	Chief Financial Officer

Filing Compare · Global Pharm Holdings Group, Inc.